仙琚製藥(002332.SZ)擬對子公司增資並投建杭州研發基地項目
格隆匯12月9日丨仙琚製藥(002332.SZ)公佈,杭州能可愛心醫療科技有限公司(“能可愛心”)系公司全資子公司(其中浙江仙琚置業有限公司(系公司全資子公司)持有能可愛心60%股權,公司持有能可愛心40%股權),該公司註冊資本為人民幣5605萬元。公司擬以自有資金人民幣9395萬元以分期出資方式(根據項目進度)對能可愛心進行增資,增資後的能可愛心註冊資本為人民幣15000萬元,仍為公司的全資子公司。
基於公司未來中長期發展規劃,公司擬在現有杭州能可愛心地塊投資建設仙琚製藥杭州研發基地,第一期投資預算為8000萬元,投資建設期為30個月(2020年1月至2022年6月),擬建造研發配套綜合大樓一棟,研發大樓兩棟,建築面積約25500平方米。該項目主要為基礎設施建設,第一期建成後將為公司杭州研發基地建設奠定硬件基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.